CK2 modulation of NF-kappaB, TP53 and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50 nm nanocapsules

Eitemau Tebyg

• Mechanism and efficacy of sub-50 nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma
  gan: Unger, Gretchen M., et al.
  Cyhoeddwyd: (2014)
• Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation
  gan: Trembley, Janeen H., et al.
  Cyhoeddwyd: (2014)
• Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α′ subunits reduces orthotopic xenograft prostate tumors in mice
  gan: Trembley, Janeen H., et al.
  Cyhoeddwyd: (2011)
• CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors
  gan: Ahmed, Khalil, et al.
  Cyhoeddwyd: (2016)
• Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells
  gan: Trembley, Janeen H., et al.
  Cyhoeddwyd: (2011)